Zalando SE

  • WKN: ZAL111
  • ISIN: DE000ZAL1111
  • Land: Deutschland

Nachricht vom 06.08.2018 | 20:22

Zalando SE: Supervisory Board authorizes Management Board to purchase own shares with a total buy-back value not exceeding EUR 90 million for long term compensation program

Zalando SE / Key word(s): Share Buyback
Zalando SE: Supervisory Board authorizes Management Board to purchase own shares with a total buy-back value not exceeding EUR 90 million for long term compensation program

06-Aug-2018 / 20:22 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Today, the Management Board of Zalando SE decided to prepare an additional share buy-back program of up to EUR 90 million after the Supervisory Board had authorized the Management Board in today's meeting to purchase own shares pursuant to § 71 (1) no. 8 AktG on the basis of the authorization granted under item 7 of the Annual General Meeting 2015 with a total buy-back value not exceeding EUR 90 million until 1 June 2020. These shares are used to hedge and discharge payment obligations under the contemplated new long term compensation program for the Members of the Management Board (long term incentive 2018). The implementation of the share buy-back is subject to resolving certain questions, in particular tax issues linked to the use of own shares. Further details of the share buy-back program will be announced separately prior to its commencement.        

Person making the notification: Dr Martin Hager, Team Lead Capital Markets
 

06-Aug-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

UniDevice AG: Rekord-Ergebnis in 2018

Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.

News im Fokus

Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2018

21. Februar 2019, 11:51

Aktueller Webcast

Ströer SE & Co. KGaA

Vorläufige Geschäftszahlen 2018

26. Februar 2019

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

21. Februar 2019